Litcius/Paper detail

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial

Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy, Naim Alkhouri, Mustafa R Bashir, Bradley Freilich, Anita Kohli, Arun Khazanchi, Muhammad Y Sheikh, Mark Leibowitz, Mary E Rinella, Mohammad S Siddiqui, Mark Kipnes, Sam E Moussa, Ziad H Younes, Meena Bansal, Seth J Baum, Brian Borg, Peter J Ruane, Paul J Thuluvath, Mildred Gottwald, Mujib Khan, Charles Chen, Liza Melchor-Khan, William Chang, Alex M DePaoli, Lei Ling, Hsiao D Lieu

2022˜The œLancet. Gastroenterology & hepatology132 citationsDOI

Topics & Concepts

MedicineInternal medicineSteatohepatitisGastroenterologyNonalcoholic steatohepatitisPhase (matter)Clinical trialPhases of clinical researchDiseaseMEDLINELiver Disease Diagnosis and TreatmentFibroblast Growth Factor ResearchLiver physiology and pathology
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial | Litcius